Three golden streams of different widths flowing from a barberry shrub, symbolising different forms of berberine
October 08, 2026

Berberine vs Dihydroberberine vs Berberine Phytosome

By SciRouter Editorial Team · Last reviewed: 9 October 2026

Dihydroberberine (a reduced form of berberine) and berberine phytosome (berberine combined with phospholipids) are made to get more berberine into the blood[1–3]. In small maker-run or maker-funded studies, both produced higher blood berberine than standard berberine[1, 2]. The one human trial comparing dihydroberberine with standard berberine that also measured blood sugar found no difference[1].

Standard berberine is poorly absorbed when swallowed[4]. For what berberine itself has shown in trials, start with our guide to berberine's benefits, doses and risks.

How we researched this. On 8 October 2026 we searched PubMed through NCBI E-utilities, read Europe PMC full text where open, and checked agency and database pages (NCCIH, LactMed, ANSES, PubChem) and ClinicalTrials.gov. Human trials and meta-analyses came first, and every animal or cell study is labelled by species. We cite only sources we opened and checked against PubMed, Crossref or the agency page: 34 in total. For each formulation study we noted who funded it or worked for its maker. SciRouter does not sell berberine and uses no affiliate links. This page is not medical advice.

Why is berberine absorption so low?

Very little swallowed berberine reaches the blood as berberine. The clearest figures come from rats, where under 1% of an oral dose got into general circulation[5, 6].

Bioavailability is the share of a swallowed dose that reaches the blood unchanged. One rat study measured it at 0.68% for berberine[5]. Another found 0.36%: about half the dose passed through the gut unabsorbed, and the small intestine removed about half[6]. These are rat figures, not human ones[5, 6].

Three things seem to hold blood levels down:

  • Pumping back out. P-glycoprotein (P-gp) is a pump in the gut lining that pushes some substances back into the gut[5]. In lab-grown human gut cells, berberine was pumped out about 30 times faster than it was taken in[7]. In rat intestine, blocking P-gp raised berberine absorption about 6-fold[8].
  • Breakdown in the gut. A 2016 review named poor absorption and first-pass metabolism (breakdown before a substance reaches general circulation) as the main barriers[4].
  • Uptake into tissues. In rats, liver exposure to berberine was about 70 times plasma exposure[6]. So low blood levels may partly reflect berberine moving into tissues[6].

In people, blood levels after 500 mg doses of standard berberine were tiny: an average peak of 0.4 ng/mL after four doses in one pilot[1] and about 77 picograms per mL after one dose in another study[2]. The two labs used different methods, so these numbers should not be compared directly[1, 2].

Blood berberine is not the whole picture. In one study, the main berberine breakdown product found in blood was berberrubine[9]. This held in healthy volunteers given one dose and in adults with high cholesterol taking berberine long term[9].

How do gut bacteria turn berberine into dihydroberberine?

In animal studies, gut bacteria turned berberine into dihydroberberine, which the gut absorbed about five times faster[10]. Inside the gut wall, it changed back into berberine before reaching the blood[10].

How swallowed berberine reaches the blood, based on animal studies Berberine is swallowed. In rats, about half passed through the gut unabsorbed. In animal studies, gut bacteria turned some berberine into dihydroberberine, which the gut absorbed about five times faster. Inside the gut wall it changed back into berberine, which then reached the liver and blood. In rats, liver exposure was about 70 times blood exposure, and under 1% of the dose reached general circulation. Berberine is swallowed About half passed through unabsorbed (rats) Gut bacteria turned some of it into dihydroberberine (animals) Dihydroberberine was absorbed about 5 times faster (animals) It changed back into berberine inside the gut wall (animals) Berberine reached the liver and blood In rats, liver exposure was about 70 times blood exposure, and under 1% of the dose reached general circulation
Simplified from studies in rats and mice; absorption in people may differ. The text in this section and the one above gives the same figures[5, 6, 10]. On a small screen, scroll the figure sideways.

Berberine carries a permanent positive charge[11]. Dihydroberberine is almost the same size but has no permanent charge[11]. A 2026 review described it as more fat-soluble and better absorbed by the gut[3]. In mice given antibiotics, less berberine was converted, blood berberine fell, and berberine's measured effects on blood fats and glucose were smaller[10]. So human studies of dihydroberberine track berberine in the blood[1, 12].

Early support for the "better absorbed" idea came from rodents[13]. In high-fat-fed rodents, dihydroberberine had larger effects than berberine on fat gain, tissue fat and insulin resistance[13]. The researchers said this was likely due to better absorption[13]. Those results have not been shown in people[1, 3].

Dihydroberberine vs berberine: what did the human studies find?

One 5-person pilot found higher blood berberine after dihydroberberine than after standard berberine, but no difference in blood sugar or insulin[1]. A second small pilot compared dihydroberberine with a different enhanced form, not with standard berberine[12].

Here is what the 2021 pilot did:

  • Participants: 5 healthy men, average age 26 and weight about 92 kg[1].
  • Design: a randomized, double-blind, placebo-controlled crossover. Each man tried every option, in an order set by chance[1].
  • Dosing: four doses per option. Three came with meals the day before[1]. The fourth came the next morning with a test meal of 30 g glucose and three slices of white bread[1].

Total exposure is the area under the curve: blood berberine added up over the 2 hours after the last dose[1].

Option (four doses each) Average peak blood berberine Total exposure over 2 hours
Placebo 0.22 ng/mL[1] 20.2 ng/mL×min[1]
Berberine 500 mg 0.4 ng/mL[1] 42.3 ng/mL×min[1]
Dihydroberberine 100 mg 3.76 ng/mL, significantly higher than berberine[1] 284.4 ng/mL×min, significantly higher than berberine[1]
Dihydroberberine 200 mg 12.0 ng/mL, but it varied widely and was not significantly different from berberine[1] 929 ng/mL×min, significantly higher than berberine but highly variable[1]

On these averages, total exposure with 100 mg dihydroberberine was about 6.7 times that with 500 mg berberine, in 5 men over 2 hours[1].

Blood sugar and insulin did not differ significantly across the four options[1].

Limits matter. Baseline berberine levels already differed between options, and blood was sampled for only 2 hours[1]. The authors said the null glucose result was likely due to the short dosing period and the men's normal insulin response[1]. The senior author was a paid advisor to the company that makes the dihydroberberine tested, and that company funded the study[1].

The second pilot gave dihydroberberine or a micellar berberine product to 9 healthy volunteers in two groups[12]. Dihydroberberine gave higher blood levels of berberine and most of its breakdown products[12]. But doses were not matched, no health outcome was measured, and a co-author owns the company group behind the micellar product[12]. A 2026 review called human trials of dihydroberberine's health effects highly limited[3].

Berberine phytosome: what is it, and what do the studies show?

Berberine phytosome is berberine combined with phospholipids (fat-like molecules) from sunflower lecithin, with pea protein and grape seed extract[2]. In a 12-person study by the ingredient's maker, it gave about 4 to 6 times the blood berberine exposure of a berberine chloride tablet[2].

The absorption study in brief:

  • Design: randomized, double-blind crossover in 12 healthy volunteers, single doses taken fasting[2].
  • Options: a 500 mg berberine chloride tablet, or one or two 550 mg phytosome tablets[2].
  • Results: exposure was about 4 times higher with one phytosome tablet and 6 times higher with two[2]. Peaks were about 77 pg/mL with berberine chloride and 572 pg/mL with two phytosome tablets[2].
  • The "10x" figure: it appears only after adjusting for the smaller amount of berberine in each phytosome tablet[2].
  • Who ran it: all authors worked for the maker[2]. No health outcomes were measured, and no side effects were seen[2].

Label math matters. In that study, each 550 mg phytosome tablet held 188 mg of berberine, about one-third of its weight[2]. So "550 mg" on a label may describe the whole complex, not the berberine inside[2]. Our guide to choosing a berberine supplement explains label checks and third-party testing.

We found three studies of phospholipid berberine on health measures, each with authors linked to the maker[2, 14–16]. Impaired fasting glucose means fasting blood sugar above normal but below the diabetes range. PCOS stands for polycystic ovary syndrome.

Study Who took part Design Dose and length What was reported Caveats
2023 trial[14] 49 overweight adults with impaired fasting glucose Randomized, double-blind, placebo-controlled Two 550 mg tablets a day, 60 days Fasting glucose, insulin, visceral (belly) fat and fat mass differed significantly from placebo, and total cholesterol and triglycerides were reported as significant at p=0.05; no adverse events[14] Small, short; effect units not in the abstract; three co-authors were maker staff in the 2021 absorption study[2]
2021 study[15] 12 women with PCOS One group, no control Two 550 mg tablets a day, 60 days Insulin resistance, inflammation markers, triglycerides and testosterone were lower; liver and kidney tests unchanged[15] No control group, so changes cannot be credited to the supplement; three authors from the maker, despite a no-conflict statement[15]
2023 trial[16] 130 women with PCOS and fertility problems, Pakistan Randomized, open-label, controlled 550 mg twice a day, 90 days Mainly reproductive and skin outcomes (outside our scope); metabolic and hormone profiles did not differ significantly between groups[16] Open-label, so everyone knew who got what; one author was a maker employee[16]

What about micellar berberine?

Micellar berberine is another enhanced form with small, maker-linked studies. At the same 500 mg dose, it gave about six times the 24-hour blood exposure of standard berberine in 10 healthy volunteers[17].

A 30-day crossover study of 1,000 mg a day in 19 healthy adults found no significant changes versus placebo in liver or kidney markers, and no adverse events[18]. A co-author of both studies owns the company group behind the product[17, 18].

How do the forms compare side by side?

Standard berberine has by far the most human trials[19, 20]. The enhanced forms rest on a handful of small studies, all funded by, or with authors linked to, a company behind one of the forms tested[1, 2, 12, 14–18].

A meta-analysis pools many trials. "Exposure" means total blood berberine over the sampling time.

Form What it is Human absorption data Human outcome trials Doses studied Evidence depth
Standard berberine (HCl or chloride salt) Plain berberine salt; positively charged[11] Low: 0.4 ng/mL average peak after 500 mg doses[1] Meta-analyses of 18 trials (1,788 adults) for blood fats and 20 trials (1,761 people) for glucose[19, 20] 900–1,500 mg a day for 4–24 weeks[19]; 1.2 g a day in a 409-person trial[21] Deepest, though 15 of the 18 lipid trials were in mainland China or Hong Kong[19]
Dihydroberberine Uncharged form that turned back into berberine in the gut wall in animals[10, 11] Higher than 500 mg berberine in 5 men[1]; higher than a micellar form in 9 people, doses not matched[12] No outcome trials found; the 5-person pilot found no glucose or insulin difference[1, 3] 100 or 200 mg, four doses over about a day[1] Very thin; maker-funded[1]
Berberine phytosome Berberine combined with phospholipids; a 550 mg tablet held 188 mg of berberine[2] About 4–6 times the exposure of berberine chloride in 12 people, single doses[2] One placebo-controlled trial (49 adults), one uncontrolled study (12 women), one open-label trial (130 women)[14–16] 550 mg tablets, two a day[14–16] Limited; maker-linked authors on all four studies[2, 14–16]
Micellar berberine Berberine in an oil-and-water (emulsified) matrix[18] About 6 times the exposure of standard berberine at 500 mg in 10 people[17] One 30-day safety study in 19 healthy adults[18] 500 mg once; 1,000 mg a day for 30 days[17, 18] Very thin; maker-linked[17, 18]

Does better absorption mean better results?

Not necessarily. Higher blood berberine is a measured step, not proof of larger effects on blood sugar, cholesterol or weight[1, 3].

  • The one direct test was null. Dihydroberberine raised blood berberine but did not change glucose or insulin compared with standard berberine, in 5 men over 2 hours[1].
  • Blood is not the whole story. In mice, gut bacteria shaped both blood berberine and its measured effects[10].
  • Poor absorption did not rule out effects. A 12-week, four-group trial in China enrolled 409 adults with newly diagnosed type 2 diabetes[21]. HbA1c (a 3-month blood sugar average) fell 0.99 percentage points with berberine 1.2 g a day, versus 0.59 with placebo[21]. The authors linked part of this to gut bacteria and bile acids, in secondary analyses[21].
  • Multipliers are not comparable. Each study used its own comparator, dose and lab method[1, 2, 17].

Is dihydroberberine or phytosome safer than standard berberine?

We found no study showing that dihydroberberine or phytosome is gentler than standard berberine. In the only dihydroberberine trial with a standard-berberine arm, a 5-man pilot, more adverse events (unwanted symptoms) were logged with dihydroberberine 100 mg than with berberine 500 mg, but the numbers were tiny[1].

Each form delivers berberine to the blood, so the usual berberine cautions apply to all of them[1, 2].

  • Side effects in the pilot. Two of the 5 men reported 11 adverse events in total: 6 with dihydroberberine 100 mg, 3 with placebo, 1 with dihydroberberine 200 mg and 1 with berberine 500 mg[1]. All but one were mild[1]. The 12-person phytosome absorption study saw no side effects[2].
  • Heart rhythm. hERG is a potassium channel that helps the heart reset between beats, and blocking it can lengthen the QT interval on a heart tracing (ECG)[22]. In cell studies, both berberine and dihydroberberine blocked hERG[23, 24]. In one test using frog egg cells, dihydroberberine reduced the hERG current by about 30%, versus about 16% for berberine at the same concentration[22]. The authors noted that berberine's effect in that test was weaker than earlier studies had reported[22]. These are lab results, not human ones[22–24]. A 2026 review called hERG inhibition a possible dihydroberberine risk that needs careful study[3]. A 2026 case report described a 61-year-old man with a dangerous heart rhythm while taking berberine, dihydroberberine and other supplements[25]. The authors also pointed to low magnesium and drug interactions[25].
  • Animal toxicology. In a 90-day study in rats, no adverse effects were seen even at the highest dihydroberberine dose tested, 100 mg per kg of body weight a day[26]. Standard bacterial, cell and animal tests found no genetic damage, and the abstract reported no heart-rhythm measurements[26]. A company that sponsors a registered dihydroberberine trial funded the work[26, 27]. Both authors reported advisory ties to that company[26]. Rat results do not show that a supplement is safe for people.
  • Drug interactions. The only human enzyme study we found used standard berberine: 300 mg three times daily for 2 weeks slowed CYP2D6, CYP2C9 and CYP3A4, liver enzymes that clear many common medicines, in healthy men[28]. We found no interaction study of the enhanced forms.
  • Blood sugar. In a 2023 meta-analysis of placebo-controlled trials, berberine lowered fasting glucose by 0.52 mmol/L more than placebo (18 trials, 1,522 people with and without diabetes)[20]. France's food-safety agency, ANSES, lists low blood sugar among its risks[29].
  • Pregnancy and breastfeeding. In lab and rat studies, berberine pushed bilirubin off its carrier protein, a concern for newborns[30, 31]. NIH says goldenseal, a berberine-containing herb, should not be used in pregnancy or breastfeeding[32], and ANSES advises the same for berberine supplements[29].

Important: Berberine in any form is not recommended during pregnancy or breastfeeding, and it can interact with many medicines[29, 32]. If you take a glucose-lowering or other prescription medicine, ask your prescriber or pharmacist before adding any berberine product, to reduce the chance of low blood sugar or an interaction.

Our page on berberine safety, side effects and interactions covers these risks in more detail.

Which form has the strongest evidence?

Standard berberine has the most human evidence, with meta-analyses pooling 18 to 23 trials[19, 20, 33]. Dihydroberberine and phytosome raise blood levels in small studies, but better absorption has not been shown to give better results[1, 3].

When comparing products, ask how much actual berberine each dose holds and whether berberine is safe with your medicines. For the wider picture, read our full review of the berberine evidence.

A dihydroberberine trial still to report

In October 2026, ClinicalTrials.gov listed a placebo-controlled dihydroberberine trial with no posted results[27]. It planned 400 mg a day for 6 weeks in an estimated 54 adults with prediabetes, with the gut hormone GLP-1 after a meal as its main outcome[27]. Its estimated completion date, March 2026, had passed[27]. Its sponsor was the company that funded the rat toxicology study above[26, 27].

Get our plain-English longevity research digest

Short, sourced summaries of new longevity research, written in plain English. No product pitches. Unsubscribe anytime.

Frequently asked questions

What is dihydroberberine good for?

Dihydroberberine was developed as a better-absorbed form of berberine[1]. In a 5-person pilot, 100 mg doses raised blood berberine more than 500 mg doses of standard berberine, but blood sugar and insulin did not differ[1]. A 2026 review found that dihydroberberine's metabolic evidence comes mainly from cell and animal studies[3].

Is dihydroberberine safer than berberine?

No study we found has shown dihydroberberine to be safer than berberine. In a 5-man pilot, 2 men logged 11 mostly mild unwanted symptoms: 6 with 100 mg dihydroberberine, 3 with placebo, and 1 each with 200 mg dihydroberberine and 500 mg berberine, too few to compare[1]. In lab tests, dihydroberberine and berberine both blocked hERG, a heart-rhythm channel[22–24]. It delivers berberine to the blood, so berberine's interaction cautions still apply[1, 28].

Does dihydroberberine work for weight loss?

No human trial we found tested dihydroberberine on body weight. In high-fat-fed rodents, dihydroberberine had larger effects on fat gain than berberine[13]. In people, standard berberine's weight effects were small: about 0.88 kg more loss than control across 23 trials[33], and no difference from placebo in a 6-month trial of 337 adults with obesity and fatty liver[34].

How long does it take for dihydroberberine to start working?

No study we found has measured how long dihydroberberine takes to change any health outcome. The 5-person pilot sampled blood for only 2 hours after the last of four doses[1]. Blood berberine rose in that window, but blood sugar and insulin did not differ from placebo or standard berberine[1].

Is berberine HCl or phytosome better?

Standard berberine, such as berberine HCl, has far more human trials than phytosome[19, 20]. Berberine phytosome gave about 4 to 6 times the blood exposure of berberine chloride in one 12-person, single-dose study run by its maker[2]. We found no trial comparing berberine HCl and phytosome on health outcomes, so "better" is unproven.

What is berberine phytosome used for?

Berberine phytosome is a formulation designed to raise berberine absorption[2]. Its human studies measured blood berberine, blood sugar, blood fats and body fat, plus reproductive outcomes in women with polycystic ovary syndrome (PCOS)[2, 14–16]. In a 60-day trial of 49 overweight adults with impaired fasting glucose, two 550 mg tablets a day lowered fasting glucose and insulin more than placebo[14]. Every study we found had maker-linked authors, and none compared phytosome with standard berberine on health outcomes[2, 14–16].

How much berberine is in a berberine phytosome tablet?

In the maker's 2021 absorption study, a 550 mg berberine phytosome tablet held 188 mg of berberine, about one-third of its weight[2]. The rest was the phospholipid carrier and added ingredients such as pea protein and grape seed extract[2]. Products differ, so check whether a label lists the whole complex or the berberine inside.

References

  1. Moon JM, Ratliff KM, Hagele AM, et al. Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial. Nutrients. 2021. PMID: 35010998
  2. Petrangolini G, Corti F, Ronchi M, et al. Development of an Innovative Berberine Food-Grade Formulation with an Ameliorated Absorption: In Vitro Evidence Confirmed by Healthy Human Volunteers Pharmacokinetic Study. Evid Based Complement Alternat Med. 2021. PMID: 34904017
  3. Wang D, Tang Y. Dihydroberberine in metabolic disorders: Bioavailability, molecular mechanisms, toxicology, and future perspectives. Food Chem Toxicol. 2026. PMID: 42398618
  4. Liu CS, Zheng YR, Zhang YF, et al. Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia. 2016. PMID: 26851175
  5. Chen W, Miao YQ, Fan DJ, et al. Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. AAPS PharmSciTech. 2011. PMID: 21637946
  6. Liu YT, Hao HP, Xie HG, et al. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos. 2010. PMID: 20634337
  7. Maeng HJ, Yoo HJ, Kim IW, et al. P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers. J Pharm Sci. 2002. PMID: 12434406
  8. Pan GY, Wang GJ, Liu XD, et al. The involvement of P-glycoprotein in berberine absorption. Pharmacol Toxicol. 2002. PMID: 12530470
  9. Spinozzi S, Colliva C, Camborata C, et al. Berberine and its metabolites: relationship between physicochemical properties and plasma levels after administration to human subjects. J Nat Prod. 2014. PMID: 24593257
  10. Feng R, Shou JW, Zhao ZX, et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep. 2015. PMID: 26174047
  11. National Center for Biotechnology Information. Berberine (PubChem CID 2353); also Berberine chloride (CID 12456) and Dihydroberberine (CID 10217). PubChem. Accessed 8 October 2026.
  12. Chang C, Roh YS, Du M, et al. Differences in Metabolite Profiles of Dihydroberberine and Micellar Berberine in Caco-2 Cells and Humans-A Pilot Study. Int J Mol Sci. 2024. PMID: 38891813
  13. Turner N, Li JY, Gosby A, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes. 2008. PMID: 18285556
  14. Rondanelli M, Gasparri C, Petrangolini G, et al. Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial. Eur Rev Med Pharmacol Sci. 2023. PMID: 37522683
  15. Rondanelli M, Riva A, Petrangolini G, et al. Berberine Phospholipid Is an Effective Insulin Sensitizer and Improves Metabolic and Hormonal Disorders in Women with Polycystic Ovary Syndrome: A One-Group Pretest-Post-Test Explanatory Study. Nutrients. 2021. PMID: 34684666
  16. Di Pierro F, Sultana R, Eusaph AZ, et al. Effect of Berberine Phytosome on reproductive, dermatologic, and metabolic characteristics in women with polycystic ovary syndrome: a controlled, randomized, multi-centric, open-label clinical trial. Front Pharmacol. 2023. PMID: 38074133
  17. Solnier J, Zhang Y, Kuo YC, et al. Characterization and Pharmacokinetic Assessment of a New Berberine Formulation with Enhanced Absorption In Vitro and in Human Volunteers. Pharmaceutics. 2023. PMID: 38004546
  18. Ibi A, Chang C, Kuo YC, et al. A 30-Day Randomized Crossover Human Study on the Safety and Tolerability of a New Micellar Berberine Formulation with Improved Bioavailability. Metabolites. 2025. PMID: 40278369
  19. Blais JE, Huang X, Zhao JV. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs. 2023. PMID: 36941490
  20. Zhao JV, Huang X, Zhang J, et al. Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Nutr. 2023. PMID: 37598753
  21. Zhang Y, Gu Y, Ren H, et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nat Commun. 2020. PMID: 33024120
  22. Schramm A, Baburin I, Hering S, et al. HERG channel inhibitors in extracts of Coptidis rhizoma. Planta Med. 2011. PMID: 21412693
  23. Rodriguez-Menchaca A, Ferrer-Villada T, Lara J, et al. Block of HERG channels by berberine: mechanisms of voltage- and state-dependence probed with site-directed mutant channels. J Cardiovasc Pharmacol. 2006. PMID: 16424781
  24. Yu D, Lv L, Fang L, et al. Inhibitory effects and mechanism of dihydroberberine on hERG channels expressed in HEK293 cells. PLoS One. 2017. PMID: 28763460
  25. Mohammadi A, Abdalla HM, Falls N, et al. Recurrent Torsades de Pointes Precipitated by Berberine Supplement. JACC Case Rep. 2026. PMID: 42684237
  26. Lewis KD, Falk M. Toxicological assessment of dihydroberberine. Food Chem Toxicol. 2022. PMID: 35868606
  27. ClinicalTrials.gov. Effects of Dihydroberberine (DHB) on GLP-1, Glycemic Control, Appetite, and Mood in Adults With Pre-Diabetes (NCT07210684). Registry record, accessed 9 October 2026.
  28. Guo Y, Chen Y, Tan ZR, et al. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012. PMID: 21870106
  29. French Agency for Food, Environmental and Occupational Health & Safety. Use of berberine-containing plants in food supplements. ANSES. 2019.
  30. Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonate. 1993. PMID: 8513024
  31. Drugs and Lactation Database (LactMed). Goldenseal. National Institute of Child Health and Human Development. 2006, revised 2025. PMID: 30000926
  32. National Center for Complementary and Integrative Health. Goldenseal: Usefulness and Safety. NCCIH (NIH). Updated February 2025.
  33. Elahi Vahed I, Shahir-Roudi E, Nojumi S, et al. The effect of berberine on obesity indices: a systematic review and meta-analysis. Int J Obes (Lond). 2026. PMID: 41310257
  34. Lei L, Wang B, Zhao L, et al. Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. JAMA Netw Open. 2026. PMID: 41543854

This content is for education only and is not medical advice. Talk to your healthcare provider before starting any supplement, especially if you are pregnant, nursing, take medication, or have a medical condition.

more Blog posts

View all